AMO buys Pfizer's surgical ophthalmology unit

Advanced Medical Optics Inc. (AMO) brought something special to San Diegofor this week's American Society of Cataract and Refractive Surgery meeting-thesurgical ophthalmology business formerly owned by Pfizer. AMO and Pfizer on April 21 entered into a definitive agreement for AMO to acquire Pfizer's surgical ophthalmology business for $450 million in cash.

Related Videos

View All

Related Content

Researchers unravel why episodes of low blood sugar worsen eye disease in people with diabetes

January 29th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

NIH scientists create eye tissue using 3D bioprinting

January 28th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Vial partners with RecensMedical in phase 3 clinical trial

January 27th 2023

New therapies suggest potential alternatives to retinal biologics

January 27th 2023

Researchers unravel why episodes of low blood sugar worsen eye disease in people with diabetes

January 29th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

NIH scientists create eye tissue using 3D bioprinting

January 28th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Vial partners with RecensMedical in phase 3 clinical trial

January 27th 2023

New therapies suggest potential alternatives to retinal biologics

January 27th 2023

Researchers unravel why episodes of low blood sugar worsen eye disease in people with diabetes

January 29th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

NIH scientists create eye tissue using 3D bioprinting

January 28th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Vial partners with RecensMedical in phase 3 clinical trial

January 27th 2023

New therapies suggest potential alternatives to retinal biologics

January 27th 2023

Related Content

---

Researchers unravel why episodes of low blood sugar worsen eye disease in people with diabetes

Articles

---

Commercial real estate and your practice, part two with Colin Carr

Podcasts

---

NIH scientists create eye tissue using 3D bioprinting

Articles

---

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcasts

---

Vial partners with RecensMedical in phase 3 clinical trial

Articles

---

New therapies suggest potential alternatives to retinal biologics

Articles